CD2 | Jotup

Human Resource Technology Companies Announce Partnership - CD2 Learning and Performica

Retrieved on:

Monday, June 5, 2023

HR, Learning, Organization, CD2, Partnership, Morale, LMS, Tutoring, Management

LINCOLN, Neb., June 5, 2023 /PRNewswire/ -- CD2 Learning , a Nelnet Company , is pleased to announce a partnership with the human resource (HR) technology firm, Performica .

Key Points:

LINCOLN, Neb., June 5, 2023 /PRNewswire/ -- CD2 Learning , a Nelnet Company , is pleased to announce a partnership with the human resource (HR) technology firm, Performica .
The partnership between Performica and CD2 Learning creates a powerful combination of expertise in employee development and performance.
CD2 Learning helps organizations train and retain associates with a LMS platform for employee development and learning, compliance training, personalized learning paths, and content creation services.
"We look forward to a successful partnership with Performica and the benefits it will bring to our mutual customers," added Jay Breeden, president of CD2 Learning.

Bunker Hill Announces Upsized and Improved $67 Million Financing Package to Enable Completion of the Mine Restart, Offtake Agreement

Retrieved on:

Tuesday, May 23, 2023

TORONTO, May 23, 2023 (GLOBE NEWSWIRE) -- Bunker Hill Mining Corp. (CSE: BNKR) (“Bunker Hill” or the “Company) is pleased to announce the execution of a non-binding term sheet outlining an upsized and improved $67 million non-dilutive project finance package with Sprott Private Resource Streaming & Royalty Corp (“Sprott Streaming”). All figures in this news release are in US dollars unless otherwise stated.

Key Points:

Sam Ash, CEO, stated “We are excited to announce an upsized and improved project finance package that we expect to backstop the full financing of the Bunker Hill mine restart, materially strengthen our balance sheet and liquidity, and support our TSX-V application.
We are thrilled to have partnered with Sprott Streaming, who have demonstrated their commitment and support for the project each step of the way.
Including the previously funded $8 million Royalty Convertible Debenture, $6 million Series 1 Convertible Debenture (the “CD1”), and $15 million Series 2 Convertible Debenture (the “CD2”), Sprott Streaming’s total commitment to the Bunker Hill Mine restart would increase to $96 million.
Any agreement with a metal trader, in lieu of the Debt Facility, would be subject to approval by Teck and Sprott Streaming.

CD2 Learning and Easygenerator Announce Strategic Partnership to Enhance eLearning Solutions

Retrieved on:

Wednesday, May 24, 2023

Organization, CD2, Partnership, Science and technology in Asia, Tutoring, Renewable energy, Easygenerator

LINCOLN, Neb., May 24, 2023 /PRNewswire/ -- CD2 Learning (CD2), a leading provider of online learning solutions, and Easygenerator, a leading cloud-based authoring tool, are pleased to announce a strategic partnership aimed at enhancing eLearning solutions.

Key Points:

LINCOLN, Neb., May 24, 2023 /PRNewswire/ -- CD2 Learning (CD2), a leading provider of online learning solutions, and Easygenerator, a leading cloud-based authoring tool, are pleased to announce a strategic partnership aimed at enhancing eLearning solutions.
The partnership between CD2 and Easygenerator is a result of a shared vision to make eLearning more accessible, user-friendly and effective.
"Easygenerator is excited to be partnering with CD2 to deliver a seamless and efficient eLearning solution," said Faraz Ghasemi, head of partnerships at Easygenerator.
CD2 and Easygenerator are committed to continuously improving their eLearning solutions to meet the ever-changing needs of the industry.

EvolveImmune Therapeutics Reports First Results from CRISPR-Cas9 T Cell Exhaustion Screening Platform at American Association for Cancer Research (AACR) Annual Meeting 2023

Retrieved on:

Tuesday, April 18, 2023

BRANFORD, Conn., April 18, 2023 (GLOBE NEWSWIRE) -- EvolveImmune Therapeutics, an immuno-oncology company developing first-in-category, multifunctional biotherapeutics to overcome cancer-driven immunodeficiency, today announced the presentation of the first data highlighting the company’s proprietary CRISPR-Cas9 T cell exhaustion screening platform. Additionally, the company presented the latest preclinical data for EV-104, the company’s first-in-category lead solid tumor program which was created using the company’s proprietary costimulatory T cell engager platform, known as EVOLVE. These presentations were delivered at the American Association for Cancer Research (AACR) Annual Meeting 2023, which is being held April 14-19, 2023, in Orlando, Florida.

Key Points:

These presentations were delivered at the American Association for Cancer Research (AACR) Annual Meeting 2023, which is being held April 14-19, 2023, in Orlando, Florida.
In a poster presentation, the company introduced a novel CRISPR-Cas9 T cell exhaustion screen that it designed to identify molecular targets that regulate T cell exhaustion following chronic T cell receptor and CD28 costimulatory receptor activation.
EvolveImmune scientists utilized this screen to identify specific genes that promote T cell exhaustion, which are associated with different signaling and regulatory pathways than the PD-1/PD-L1 checkpoint pathway.
“We are excited to unveil our T cell exhaustion screening platform for the first time.

EvolveImmune Therapeutics Presents New Preclinical Data Demonstrating Improved Anti-Tumor Potential of Novel Costimulatory T Cell Engager Platform at Festival of Biologics Immunotherapy World Congress

Retrieved on:

Wednesday, March 22, 2023

Monoclonal antibody, Lymphoid leukemia, CD2, Immunology, Therapy, CD3, CD28, CD20, Neoplasm, Cancer, Research, Immunotherapy, Acute myeloid leukemia, CD8, Festival, Lymphocyte, EVOLVE, Pharmaceutical industry, Vaccine

BRANFORD, Conn., March 22, 2023 (GLOBE NEWSWIRE) -- EvolveImmune Therapeutics, an immuno-oncology company developing first-in-category, multifunctional biotherapeutics to overcome cancer-driven immunodeficiency, today announced that new preclinical data on EVOLVE™, the company’s novel costimulatory T cell engager platform, were featured in an oral presentation at the Festival of Biologics Immunotherapy World Congress. The presentation highlighted the potential of the company’s innovative integrated CD2 costimulatory strategy to overcome treatment limitations of current immunotherapies. Additionally, the company disclosed the first data for EVOLVE-105, its best-in-class CD20xCD3 multispecific T cell engager that also selectively mediates CD2 costimulation.

Key Points:

The presentation highlighted the potential of the company’s innovative integrated CD2 costimulatory strategy to overcome treatment limitations of current immunotherapies.
Additionally, the company disclosed the first data for EVOLVE-105, its best-in-class CD20xCD3 multispecific T cell engager that also selectively mediates CD2 costimulation.
Moreover, they do not provide coordinated costimulatory receptor activation to overcome T cell dysfunction and drive more effective and longer lasting anti-tumor responses.
The Festival of Biologics presentation, entitled, “A novel costimulatory T cell engager platform engineered for the treatment of immune suppressive tumors,” included key new findings for the company’s EVOLVE platform and its growing costimulatory T cell engager portfolio.

EvolveImmune Therapeutics Reports Preclinical Data Highlighting Deep and Durable Anti-Tumor Efficacy with EV-104 in Presentation at 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Retrieved on:

Thursday, November 10, 2022

GLOBE, Hematological Cancer Research Investment and Education Act, Yale Cancer Center, Leadership, Immunotherapy, Research, Acute myeloid leukemia, Lung cancer, EVOLVE, Therapy, Collection, CD2, Immunology, Neoplasm, Treatment, Society, SITC, Vaccine

BRANFORD, Conn., Nov. 10, 2022 (GLOBE NEWSWIRE) -- EvolveImmune Therapeutics, an immuno-oncology company developing first-in-category, multifunctional biotherapeutics to overcome cancer-driven immunodeficiency, today announced that new preclinical data highlighting EVOLVE™, the company’s novel costimulatory T cell engager platform, were presented at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). The results were featured in a poster presentation (#1060) entitled, “EVOLVE: a Novel Costimulatory T Cell Engager Platform Engineered for the Treatment of Immune Suppressive Tumors,” at the conference, which is being held November 8-12, 2022, in Boston.

Key Points:

Most current immunotherapies rely on the presence of pre-existing tumor-reactive T cells, which are absent or at low levels in many tumors.
Moreover, they do not provide coordinated costimulatory receptor activation to overcome T cell dysfunction and drive more effective and durable anti-tumor responses.
EvolveImmune has built a pipeline of first-in-category costimulatory T cell engager immunotherapies against both first-in-class and best-in-class cancer targets.
We are encouraged by the strong preclinical performance of our EVOLVE platform, including its promising efficacy and safety profile.

EvolveImmune Therapeutics Presents Promising Preclinical Data from Novel Costimulatory T Cell Engager Platform at American Association for Cancer Research (AACR) Special Conference on Tumor Immunology and Immunotherapy

Retrieved on:

Monday, October 24, 2022

BRANFORD, Conn., Oct. 24, 2022 (GLOBE NEWSWIRE) -- EvolveImmune Therapeutics, an immuno-oncology company developing first-in-category, multifunctional biotherapeutics to overcome cancer-driven immunodeficiency, today announced that new preclinical data highlighting EVOLVE™, the company’s novel costimulatory T cell engager platform, were presented at the American Association for Cancer Research (AACR) Special Conference on Tumor Immunology and Immunotherapy. The results were featured in a poster presentation (#B44) entitled, “EVOLVE: a Novel Costimulatory T Cell Engager Platform Engineered for the Treatment of Solid Tumors,” at the conference, which was held October 21-23, 2022, in Boston.

Key Points:

The results were featured in a poster presentation (#B44) entitled, EVOLVE: a Novel Costimulatory T Cell Engager Platform Engineered for the Treatment of Solid Tumors, at the conference, which was held October 21-23, 2022, in Boston.
Most current immunotherapies rely on the presence of pre-existing tumor-reactive T cells, which are absent or at low levels in many tumors.
Moreover, they do not provide coordinated costimulatory receptor activation to overcome T cell dysfunction and drive more effective and durable anti-tumor responses.
I am encouraged by these data and the potential of EVOLVE to break the solid tumor barrier.

NEW DELUXE EDITION OF ROBBIE WILLIAMS' 'LIFE THRU A LENS' TO BE RELEASED ON DECEMBER 2 TO CELEBRATE THE 25th ANNIVERSARY

Retrieved on:

Thursday, October 13, 2022

LOS ANGELES, Oct. 13, 2022 /PRNewswire/ -- Robbie Williams has today announced that a new deluxe edition of his multi-million-selling debut solo album, Life Thru A Lens, will be released on December 2 to celebrate the 25th anniversary of the record.

Key Points:

CD2 - Life On The Flipside; B-Sides and Bonus Tracks
Freedom (from "Freedom" CD Single 1, July 1996)
Better Days (from "Old Before I Die" CD Single 1, April 1997)
Average B-Side (from "Old Before I Die" CD Single 1, April 1997)
Making Plans For Nigel (from "Old Before I Die" CD Single 2, April 1997)
Kooks (from "Old Before I Die" CD Single 2, April 1997)
Teenage Millionaire (from "Lazy Days" CD Single 1, July 1997)
Falling In Bed (Again) (from "Lazy Days" CD Single 1, July 1997)
She Makes Me High (from "Lazy Days" CD Single 2, July 1997)
Ev'ry Time We Say Goodbye (from "Lazy Days" CD Single 2, July 1997)
Lazy Days (Original Version) (from "Millennium" CD Single 2, September 1998)
Cheap Love Song (from "South Of The Border" CD Single 1, September 1997)
Walk This Sleigh (from "Angels" CD Single 1, December 1997)
Karaoke Overkill (from "Angels" CD Single 2, December 1997)
Get the Joke (from "Angels" CD Single 2, December 1997)
Angels (acoustic version) (from "Angels" CD Single 2, December 1997)
Let Me Entertain You (Full Length Version) (from "Let Me Entertain You" CD Single 2, March 1998)
Medley Of Songs From The Motion Picture Soundtrack The Full Monty (from "Let Me Entertain You" CD Single 1, March 1998)
I Wouldn't Normally Do This Kind Of Thing (from "Let Me Entertain You" CD Single 1, March 1998)
I Am The (Res)erection (from "Let Me Entertain You" CD Single 1, March 1998)
CD3 - Work In Progress: The Making of Life Thru A Lens
Hey Little Girl (Axis Studios Demo, October / November 1996)
Old Before I Die (Crescent Moon Studios Demo, October 1996)
Lazy Days (Tower Studios Demo, January 1997)
Red Lights (Tower Studios Demo, January 1997)
Average B-Side (Westside Studios Demo, February 1997)
South of the Border (Rehearsal Recording, Spring 1997)
Killing Me Rehearsal (Rehearsal Recording, Spring 1997)
Life Thru A Lens Rehearsal (Rehearsal Recording, Spring 1997)
Let Me Entertain You (Live at The Forum, London 3 June 1998)
I Wouldn't Normally Do This Kind Of Thing (Live at The Forum, London 3 June 1998)
Clean (Live at The Forum, London 3 June 1998)
South Of The Border (Live at The Forum, London 3 June 1998)
Average 'B' Side (Live at The Forum, London 3 June 1998)
Baby Girl Window (Live at The Forum, London 3 June 1998)
One Of God's Better People (Live at The Forum, London 3 June 1998)
There She Goes (Live at The Forum, London 3 June 1998)
Killing Me (Live at The Forum, London 3 June 1998)
Life Thru A Lens (Live at The Forum, London 3 June 1998)
Teenage Millionaire (Live at The Forum, London 3 June 1998)
Lazy Days (Live at The Forum, London 3 June 1998)
Ego A Go Go (Live at The Forum, London 3 June 1998)
Old Before I Die (Live at The Forum, London 3 June 1998)
Angels (Live at The Forum, London 3 June 1998)
Back For Good (Live at The Forum, London 3 June 1998)
View original content to download multimedia: https://www.prnewswire.com/news-releases/new-deluxe-edition-of-robbie-wi...

ALOGIC Launches New Range of 4k Dual Display, Compact, Universal Docking Stations

Retrieved on:

Tuesday, October 4, 2022

NEWARK, Calif., Oct. 04, 2022 (GLOBE NEWSWIRE) -- ALOGIC, the leading provider of connectivity, mobility, and end-user computing solutions for IT, enterprises, and consumers, announces the availability of its new, compact range of Laptop Docking Stations – CD2 and CH2, across the globe.

Key Points:

Both the Universal Docks with either twin DisplayPort or HDMI Ports, enable connecting two external displays with up to 4K 60 Hz resolutions with 100W power passthrough.
The CD2 and CH2 compact, 4k Universal Docking Stations are designed to make every desk set-up more functional, flexible and productive, offering variety of ports to suit users connectivity requirements, he added.
For further information, visit: Alogic, CD2 4k Universal Docking Station and Alogic, CH2 4k Universal Docking Station
ALOGIC has created a niche for itself providing state-of-the-art tech solutions for the ever-transforming and fast-paced end user computing space globally.
Headquartered in California, US, ALOGIC has presence across 28 countries globally and is committed to strategically growing its footprints at a sturdy pace.

ALOGIC Launches New Range of 4k Dual Display, Compact, Universal Docking Stations

Retrieved on:

Monday, October 3, 2022

MELBOURNE, Australia, Oct. 04, 2022 (GLOBE NEWSWIRE) -- ALOGIC, the leading provider of connectivity, mobility, and end-user computing solutions for IT, enterprises, and consumers, announces the availability of its new, compact range of Laptop Docking Stations – CD2 and CH2, across the globe.

Key Points:

Both the Universal Docks with either twin DisplayPort or HDMI Ports, enable connecting two external displays with up to 4K 60 Hz resolutions with 100W power passthrough.
The CD2 and CH2 compact, 4k Universal Docking Stations are designed to make every desk set-up more functional, flexible and productive, offering variety of ports to suit users connectivity requirements, he added.
For further information, visit: Alogic, CD2 4k Universal Docking Station and Alogic, CH2 4k Universal Docking Station
ALOGIC has created a niche for itself providing state-of-the-art tech solutions for the ever-transforming and fast-paced end user computing space globally.
Headquartered in California, US, ALOGIC has presence across 28 countries globally and is committed to strategically growing its footprints at a sturdy pace.